Bradley Foster & Sargent Inc. CT Increases Holdings in CVS Health Corp (CVS)

Bradley Foster & Sargent Inc. CT raised its holdings in shares of CVS Health Corp (NYSE:CVS) by 55.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 45,237 shares of the pharmacy operator’s stock after purchasing an additional 16,226 shares during the quarter. Bradley Foster & Sargent Inc. CT’s holdings in CVS Health were worth $2,964,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in CVS. Avestar Capital LLC lifted its holdings in shares of CVS Health by 19.6% during the fourth quarter. Avestar Capital LLC now owns 951 shares of the pharmacy operator’s stock worth $57,000 after buying an additional 156 shares in the last quarter. Griffin Asset Management Inc. lifted its holdings in shares of CVS Health by 1.4% during the third quarter. Griffin Asset Management Inc. now owns 11,438 shares of the pharmacy operator’s stock worth $900,000 after buying an additional 160 shares in the last quarter. Adviser Investments LLC lifted its holdings in shares of CVS Health by 5.4% during the fourth quarter. Adviser Investments LLC now owns 3,163 shares of the pharmacy operator’s stock worth $207,000 after buying an additional 162 shares in the last quarter. Visionary Asset Management Inc. lifted its holdings in shares of CVS Health by 3.8% during the fourth quarter. Visionary Asset Management Inc. now owns 4,911 shares of the pharmacy operator’s stock worth $322,000 after buying an additional 178 shares in the last quarter. Finally, Lee Danner & Bass Inc. lifted its holdings in shares of CVS Health by 0.4% during the fourth quarter. Lee Danner & Bass Inc. now owns 45,077 shares of the pharmacy operator’s stock worth $2,953,000 after buying an additional 178 shares in the last quarter. 87.22% of the stock is owned by institutional investors and hedge funds.

Shares of NYSE CVS opened at $67.79 on Thursday. The company has a current ratio of 2.44, a quick ratio of 1.94 and a debt-to-equity ratio of 1.66. CVS Health Corp has a 52 week low of $60.14 and a 52 week high of $82.15. The firm has a market capitalization of $66.34 billion, a P/E ratio of 11.49, a P/E/G ratio of 0.88 and a beta of 1.03.

The business also recently declared a quarterly dividend, which was paid on Monday, February 4th. Investors of record on Friday, January 25th were given a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 2.95%. The ex-dividend date of this dividend was Thursday, January 24th. CVS Health’s payout ratio is currently 33.90%.

In related news, insider Larry J. Merlo sold 166,368 shares of the firm’s stock in a transaction on Friday, February 1st. The stock was sold at an average price of $64.51, for a total value of $10,732,399.68. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO David M. Denton sold 25,159 shares of the firm’s stock in a transaction on Thursday, November 29th. The stock was sold at an average price of $80.13, for a total value of $2,015,990.67. Following the completion of the transaction, the chief financial officer now owns 403 shares in the company, valued at approximately $32,292.39. The disclosure for this sale can be found here. Insiders sold 435,534 shares of company stock worth $29,245,258 in the last 90 days. 0.53% of the stock is owned by company insiders.

CVS has been the subject of a number of research reports. Royal Bank of Canada set a $99.00 target price on CVS Health and gave the stock a “buy” rating in a report on Tuesday, October 23rd. Morgan Stanley set a $100.00 target price on CVS Health and gave the stock a “buy” rating in a report on Wednesday, November 7th. Cantor Fitzgerald reissued a “buy” rating and set a $96.00 target price on shares of CVS Health in a report on Thursday, January 3rd. UBS Group initiated coverage on CVS Health in a report on Thursday, January 17th. They set a “buy” rating and a $75.00 target price for the company. Finally, Leerink Swann lifted their target price on CVS Health from $85.00 to $95.00 and gave the stock a “positive” rating in a report on Thursday, November 8th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and thirteen have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $91.79.

TRADEMARK VIOLATION NOTICE: This piece was first published by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another domain, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2019/02/14/bradley-foster-sargent-inc-ct-increases-holdings-in-cvs-health-corp-cvs.html.

About CVS Health

CVS Health Corporation, together with its subsidiaries, provides integrated pharmacy health care services. It operates through Pharmacy Services and Retail/LTC segments. The Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, Medicare Part D services, mail order, specialty pharmacy and infusion services, retail pharmacy network management services, prescription management systems, clinical services, disease management programs, and medical pharmacy management services.

Read More: Why Dividend Stocks May Be Right for You

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corp (NYSE:CVS).

Institutional Ownership by Quarter for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply